Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndromes

Seminars in Hematology

Volumn 49, Issue 4, 2012, Pages 342-349

  Platzbecker, Uwe ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; AZACITIDINE; BUSULFAN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; FLUDARABINE; HYPOMETHYLATING AGENT; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL SELECTION; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CYTOGENETICS; DISEASE CONTROL; DONOR LYMPHOCYTE INFUSION; DONOR SELECTION; DRUG EFFICACY; FEASIBILITY STUDY; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOCOMPATIBILITY; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRON OVERLOAD; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT MONITORING; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; WHOLE BODY RADIATION;

AGED; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84867613291     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.07.003     Document Type: Article

References (53)

1. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
2. Martino R., Iacobelli S., Brand R., et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using BLA-identical sibling donors in myelodysplastic syndromes. Blood 2006, 108:836-846.
3. Lim Z., Brand R., Martino R., et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol 2010, 28:405-411.
4. McClune B.L., Weisdorf D.J., Pedersen T.L., et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010, 28:1878-1887.
5. Barrett A.J., Savani B.N. Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol 2008, 45:49-59.
6. Deeg H.J. Optimization of transplant regimens for patients with myelodysplastic syndrome (MDS). Hematology Am Soc Hematol Educ Program 2005, 16773.
7. Alessandrino E.P., Della Porta M.G., Bacigalupo A., et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008, 112:895-902.
8. Armand P., Kim H.T., DeAngelo D.J., et al. Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant 2007, 13:655-664.
9. Schanz J., Tuchler H., Sole F., et al. Proposal of a new, comprehensive cytogenetic scoring system for primary MDS. J Clin Oncol 2012, 30:820-825.
10. Scott B.L., Wells D.A., Loken M.R., et al. Validation of a flow cytometric scoring system as a prognostic indicator for post-transplant outcome in patients with MDS. Blood 2008, 112:2681-2686.
11. Cutler C.S., Lee S.J., Greenberg P., et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004, 104:579-585.
12. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
13. Lubbert M., Bertz H., Ruter B.H., Mertelsmann R.H., Finke J. Non-intensive AML/MDS treatment with low-dose decitabine prior to reduced-intensity conditioning (RIC) and allogeneic blood stem cell transplantation of older patients. Blood 2006, 108:406B.
14. Field T., Perkins J., Huang Y., et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010, 45:255-260.
15. Koreth J., Pidala J., Deeg H.J., et al. A decision analysis of reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation for older patients with de-novo myelodysplastic syndrome (MDS): early transplantation offers survival benefit in higher-risk MDS. Blood 2011, [abstract].
16. Platzbecker U., Schetelig J., Finke J., et al. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine. Biol Blood Marrow Transplant 2012 May 11, [Epub ahead of print].
17. Platzbecker U., Hofbauer L.C., Ehninger G., Holig K. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res 2012, 36:525-536.
18. Bejar R., Stevenson K., Abdel-Wahab O., et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011, 364:2496-2506.
19. de Witte T., Suciu S., Verhoef G., et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001, 98:2326-2331.
20. Castro-Malaspina H., Jabubowski A.A., Papadopoulos E.B., et al. Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transplant 2008, 14:458-468.
21. Scott B.L., Storer B., Loken M.R., et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005, 11:65-73.
22. Platzbecker U., Thiede C., Fuessel M., et al. Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 2006, 20:707-714.
23. Schmid C., Schleuning M., Ledderose G., Tischer J., Kolb H.J. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 2005, 23:5675-5687.
24. Sorror M.L. Comorbidities and outcomes: advancing the field comes at a price. Biol Blood Marrow Transplant 2011, 17:1721-1723.
25. Sockel K., Ehninger G., Hofbauer L.C., Platzbecker U. Optimizing management of myelodysplastic syndromes post-allogeneic transplantation. Exp Rev Hematol 2011, 4:669-680.
26. Deeg H.J., Scott B.L. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012 July 5, [Epub ahead of print].
27. Campregher P.V., Gooley T., Scott B.L., et al. Results of donor lymphocyte infusions for relapsed myelodysplastic syndrome after hematopoietic cell transplantation. Bone Marrow Transplant 2007, 40:965-971.
28. Porter D.L., Antin J.H. Donor leukocyte infusions in myeloid malignancies: new strategies. Best Practice Res Clin Haematol 2006, 19:737-755.
29. Schmid C., Labopin M., Nagler A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007, 25:4938-4945.
30. Guieze R., Jouinot A., Itzykson R., et al. Azacytidine (AZA) in relapsed MDS and AML after allogeneic stem cell transplantation (allo-HSCT): results of the French ATU program. Blood 2010, 116:553-554.
31. Czibere A., Bruns I., Kroger N., et al. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 2010, 45:872-876.
32. Goodyear O., Agathanggelou A., Novitzky-Basso I., et al. Induction of a CD8(+) T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 2010, 116:1908-1918.
33. Lubbert M., Bertz H., Wasch R., et al. Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 2010, 45:627-632.
34. Schroeder T., Czibere A., Kroger N., et al. Phase II study of azacitidine (Vidaza (R), Aza) and donor lymphocyte infusions (DLI) as first salvage therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) relapsing after allogeneic hematopoietic stem cell transplantation (allo-SCT): final results from the AZARELA-trial (NCT-00795548). Blood 2011, 118:300.
35. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2010, 116:5420-5431.
36. Fenaux P., Giagounidis A., Selleslag D., et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with low-/intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011, 118:3765-3776.
37. Chang D.H., Liu N., Klimek V., et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006, 108:618-621.
38. Sockel K., Greiner J., Trenschel R., et al. Early lenalidomide maintenance to prevent relapse of high-risk MDS and AML patients with del(5q) following allogeneic HCT-results of the "LENAMAINT" trial. Blood 2011, 118:1320.
39. Kneppers E., van der Holt B., Kersten M.J., et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial. Blood 2011, 118:2413-2419.
40. Bornhauser M., Elschlaegel U., Platzbecker U., et al. Monitoring of donor chimerism in sorted CD34(+) peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation. Haematologica 2009, 94:1613-1617.
41. Sloand E.M., Melenhorst J.J., Tucker Z.C.G., et al. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 2011, 117:2691-2699.
42. Platzbecker U., Wermke M., Radke J., et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 2012, 26:381-389.
43. Platzbecker U., Deeg H.J. Graft-versus-host disease. Hemopoietic stem cell transplantation 2004, 15984. Humana Press, New York. R.J. Soiffer (Ed.).
44. Platzbecker U., Von Bonin M., Goekkurt E., et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant 2009, 15:101-108.
45. Cutler C., Li S.L., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
46. Platzbecker U., Bornhauser M. SOS for veno-occlusive disease: defibrotide prophylaxis. Lancet 2012, 379:1277-1278.
47. Anasetti C., Logan B.R., Lee S.J., et al. Increased incidence of chronic graft-versus-host disease (GVHD) and no survival advantage with filgrastim-mobilized peripheral blood stem cells (PBSC) compared to bone marrow (BM) transplants from unrelated donors: results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0201, a phase III, prospective, randomized trial. Blood 2011, 118:3.
48. Socie G., Schmoor C., Bethge W.A., et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011, 117:6375-6382.
49. Luznik L., Jones R.J., Fuchs E.J. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol 2010, 17:493-499.
50. Platzbecker U., Bornhauser M., Germing U., et al. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant 2008, 14:1217-1225.
51. Wermke M., Schmidt A., Middeke J.M., et al. Systemic iron overload in patients undergoing allogeneic stem cell transplantation - a magnetic resonance imaging based study in 81 AML and MDS patients. Blood 2011, 118:227-228.
52. Armand P., Sainvil M.M., Kim H.T., et al. Does iron overload really matter in stem cell transplantation?. Am J Hematol 2012, 118.
53. Al Ali H.K., Jaekel N., Nass A., et al. The oral iron chelator deferasirox for treatment of transfusional iron overload after allogeneic hematopoietic cell transplantation does not appear to interfere with the calcineurin inhibitor cyclosporin trough serum levels. Blood 2010, 116:762.